{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:04:06Z","timestamp":1768194246908,"version":"3.49.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"DOI":"10.3389\/fgene.2025.1658636","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:13:00Z","timestamp":1757909580000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The potential clinical and public health implications of presymptomatic genetic testing for transthyretin amyloidosis in African American\/Black adults in the United States"],"prefix":"10.3389","volume":"16","author":[{"given":"Inderjeet","family":"Bharaj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simar J.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juzer","family":"Munaim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harneet","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Sabrowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Boshara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc A.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine H.","family":"Brendish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandesh","family":"Dev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayowa A.","family":"Osundiji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-Targeting and gene editing therapies for transthyretin amyloidosis","volume":"19","author":"Aimo","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"B2","first-page":"951","article-title":"The legacy of tuskegee and trust in medical care: is tuskegee responsible for race differences in mistrust of medical care?","volume":"97","author":"Brandon","year":"2005","journal-title":"J. Natl. Med. Assoc."},{"key":"B3","doi-asserted-by":"publisher","first-page":"994","DOI":"10.7326\/M21-4109","article-title":"The challenge of genetic variants of uncertain clinical significance: a narrative review","volume":"175","author":"Burke","year":"2022","journal-title":"Ann. Intern Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cnur.2023.11.009","article-title":"Promoting health equity among marginalized and vulnerable populations","volume":"59","author":"Campinha-Bacote","year":"2024","journal-title":"Nurs. Clin. North Am."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2025.07.011","article-title":"Transthyretin amyloid cardiomyopathy: evolving therapies, expanding hope","author":"Costabel","year":"2025","journal-title":"Prog. Cardiovasc Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ajhg.2021.03.010","article-title":"Machine learning-based reclassification of germline variants of unknown significance: the RENOVO algorithm","volume":"108","author":"Favalli","year":"2021","journal-title":"Am. J. Hum. Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13046-020-01554-6","article-title":"Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers","volume":"39","author":"Federici","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1056\/NEJMoa2412309","article-title":"CRISPR-Cas9 gene editing with nexiguran ziclumeran for ATTR cardiomyopathy","volume":"391","author":"Fontana","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B9","first-page":"S70","article-title":"Rationale and design of ACT-EARLY, the acordamidis transthyretin amyloidosis prevention trial","volume":"31","author":"Garcia-Pavia","year":"2024","journal-title":"Amyloid J. Protein Fold. Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"103129","DOI":"10.1016\/j.cpcardiol.2025.103129","article-title":"Tafamidis: a game changer in transthyretin cardiomyopathy? A systematic review and meta-analysis of safety and efficacy","volume":"50","author":"Hussain","year":"2025","journal-title":"Curr. Probl. Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","article-title":"Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 african-americans","volume":"22","author":"Jacobson","year":"2015","journal-title":"Amyloid"},{"key":"B12","doi-asserted-by":"publisher","first-page":"152058","DOI":"10.1016\/j.semperi.2025.152058","article-title":"Prenatal genomic sequencing: navigating uncertainty","volume":"49","author":"Jeanne","year":"2025","journal-title":"Semin. Perinatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/jgc4.1075","article-title":"Patients' perspectives of variants of uncertain significance and strategies for uncertainty management","volume":"28","author":"Makhnoon","year":"","journal-title":"J. Genet. Couns."},{"key":"B14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s12687-018-0375-3","article-title":"Experiences of patients seeking to participate in variant of uncertain significance reclassification research","volume":"10","author":"Makhnoon","year":"","journal-title":"J. Community Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ. Heart Fail"},{"key":"B18","doi-asserted-by":"publisher","first-page":"100819","DOI":"10.1016\/j.gim.2023.100819","article-title":"How do members of the public expect to use variants of uncertain significance in their health care? A population-based survey","volume":"25","author":"Mighton","year":"2023","journal-title":"Genet. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.hfc.2024.03.006","article-title":"Genotype-phenotype correlations in ATTR amyloidosis: a clinical update","volume":"20","author":"Monda","year":"2024","journal-title":"Heart Fail Clin."},{"key":"B20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jchf.2022.11.009","article-title":"Racial and genetic differences: possible health disparities in transthyretin amyloid cardiomyopathy patients?","volume":"11","author":"Muller","year":"2023","journal-title":"JACC Heart Fail"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","article-title":"Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis","volume":"29","author":"Obici","year":"2016","journal-title":"Curr. Opin. Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jgc4.1613","article-title":"The goldilocks conundrum: disclosing discrimination risks in informed consent","volume":"31","author":"Prince","year":"2022","journal-title":"J. Genet. Couns."},{"key":"B23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT","volume":"9","author":"Rapezzi","year":"2021","journal-title":"JACC Heart Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/jamacardio.2023.1525","article-title":"Age dependency of cardiovascular outcomes with the amyloidogenic pV142I transthyretin variant among black individuals in the US","volume":"8","author":"Selvaraj","year":"2023","journal-title":"JAMA Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1001\/jama.2024.4467","article-title":"Cardiovascular burden of the V142I transthyretin variant","volume":"331","author":"Selvaraj","year":"2024","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e002558","DOI":"10.1161\/CIRCHEARTFAILURE.115.002558","article-title":"Transthyretin cardiac amyloidosis in black Americans","volume":"9","author":"Shah","year":"2016","journal-title":"Circ. Heart Fail"},{"key":"B27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/ejhg.2012.174","article-title":"Quality in genetic counselling for presymptomatic testing--clinical guidelines for practice across the range of genetic conditions","volume":"21","author":"Skirton","year":"2013","journal-title":"Eur. J. Hum. Genet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3390\/jpm11010049","article-title":"Genomic screening identifies individuals at high risk for hereditary transthyretin amyloidosis","volume":"11","author":"Soper","year":"2021","journal-title":"J. Pers. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s12170-021-00670-y","article-title":"Racial and ethnic disparities in transthyretin cardiac amyloidosis","volume":"15","author":"Spencer-Bonilla","year":"2021","journal-title":"Curr. Cardiovasc Risk Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"116813","DOI":"10.1016\/j.jns.2020.116813","article-title":"Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies","volume":"414","author":"Ueda","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/jalm\/jfad093","article-title":"Cost effectiveness of genomic population health screening in adults: a review of modeling studies and future directions","volume":"9","author":"Wildin","year":"2024","journal-title":"J. Appl. Lab. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2025.1658636\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T04:13:01Z","timestamp":1757909581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2025.1658636\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":32,"alternative-id":["10.3389\/fgene.2025.1658636"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2025.1658636","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"article-number":"1658636"}}